Re: 'Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes' by Nutman et al

Affiliations

Free article

Comment

S Karakonstantis. Clin Microbiol Infect. 2020 Sep.

Free article

. 2020 Sep;26(9):1274.

doi: 10.1016/j.cmi.2020.04.043. Epub 2020 May 8.

¹ School of Medicine, University of Crete, Heraklion, Crete, Greece. Electronic address: stamatiskarakonstantis@gmail.com.

No abstract available

Comment in

Re: 'Colistin plus meropenem for carbapenem-resistant gram-negative infections: in vitro synergism is not associated with better clinical outcomes'-Author's reply.
Nutman A, Carmeli Y. Nutman A, et al. Clin Microbiol Infect. 2020 Sep;26(9):1275. doi: 10.1016/j.cmi.2020.05.010. Epub 2020 May 25. Clin Microbiol Infect. 2020. PMID: 32464182 No abstract available.

Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes.
Nutman A, Lellouche J, Temkin E, Daikos G, Skiada A, Durante-Mangoni E, Dishon-Benattar Y, Bitterman R, Yahav D, Daitch V, Bernardo M, Iossa D, Zusman O, Friberg LE, Mouton JW, Theuretzbacher U, Leibovici L, Paul M, Carmeli Y; AIDA Study Group. Nutman A, et al. Clin Microbiol Infect. 2020 Sep;26(9):1185-1191. doi: 10.1016/j.cmi.2020.03.035. Epub 2020 Apr 3. Clin Microbiol Infect. 2020. PMID: 32251844 Clinical Trial.